Palbociclib

Palbociclib specifically targets and inhibits the activity of CDK4 and CDK6, two proteins that are involved in the regulation of the cell cycle. By blocking these proteins, Palbociclib prevents the cancer cells from progressing through the cell cycle and dividing. This slows down or stops the growth of tumors, especially in HR-positive, HER2-negative breast cancer.